Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.

Novo Nordisk (NVO) recently experienced a downgrade from TD Cowen, driven by concerns over its long-term duopoly status in the burgeoning GLP-1 market. The investment bank cited the rapid emergence of formidable competitors, notably Eli Lilly (LLY), whose own GLP-1 offerings are gaining significant traction. This development signals a potential plateau in NVO's extraordinary growth trajectory, which has been largely fueled by the success of its blockbuster weight-loss drugs, Ozempic and Wegovy. The competitive landscape is intensifying as more pharmaceutical companies dedicate substantial resources to developing their own GLP-1 agonists, aiming to capture a share of this highly profitable sector. For investors, this downgrade underscores the evolving dynamics within the pharmaceutical industry. While Novo Nordisk remains a dominant player, the era of unchallenged market leadership for its GLP-1 drugs appears to be drawing to a close. The entry of new, effective treatments could dilute NVO's market share and potentially pressure profit margins in the coming years. Investors must now assess how the company's innovation pipeline and strategic responses will fare against this heightened competition, particularly as more tailored and potentially more efficacious GLP-1 or multi-agonist therapies reach the market. Looking ahead, the key catalyst will be the regulatory review and commercial launch of new GLP-1 drugs from rivals. Any approvals or stronger-than-expected sales figures for these new entrants could further validate TD Cowen's concerns and recalibrate market expectations for Novo Nordisk's future growth. The broader market will be closely watching for any signs of differentiation or superior efficacy among the